Dr. Weeks’ Comment: What does your cardiologist think about chelation therapy (EDTA chelation therapy) ? Has he or she read the research?
“…In stable post-MI patients on evidence-based medical therapy, the combination of oral high-dose vitamins and chelation therapy compared with double placebo reduced clinically important cardiovascular events to an extent that was both statistically significant and of potential clinical relevance.
When the TACT study on chelation was published by JAMA it but they were very tricky such that the positive outcome (see above) was buried and the media was instructed that the study was not important. All the media blithly went along with the JAMA conclusions except Forbes magazine (for reasons which are confidential). Forbes loved the study.
This report below is not biased as was the JAMA report. The conclusion is clear: EDTA worked and the findings were relevant!
Dr. Garry Gordon, DO , a father of chelation therapy wrote me this:
” Harvard published in Circulation that bone lead is far more predictive than blood lead. And Clair Patterson of Cal Tech was honored by Cosmos for his life’s work proving that bone lead levels today are dangerously elevated averaging over 1000 times the historic levels he measured in bones before the industrial age just 700 years ago. My point is that your knowledge of chelation should lead you to tell patients that lead is far more important than cholesterol lowering. That way you might have patients get one IV a month for the first few years but always assist lead detoxing with oral and then keep them oral for life…”
What is the best oral chelator of lead and other toxins – Clear TRS – the systemic and intracellular toxic removal system (the product is called CLEAR TRS) linked with the clinoptilolite crystals. (BONUS: Clear TRS also helps with cancer read this !)
EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.
REF Am Heart J. 2014 Jul;168(1):37-44.e5. doi: 10.1016/j.ahj.2014.02.012. Epub 2014 Apr 2.
AU Lamas GA1, Boineau R2, Goertz C3, Mark DB4, Rosenberg Y2, Stylianou M2, Rozema T5, Nahin RL6, Terry Chappell L7, Lindblad L4, Lewis EF8, Drisko J9, Lee KL4.
ABSTRACT: Disodium ethylenediaminetetraacetic acid (EDTA) reduced adverse cardiac outcomes in a factorial trial also testing oral vitamins. This report describes the intent-to-treat comparison of the 4 factorial groups overall and in patients with diabetes.
METHODS: This was a double-blind, placebo-controlled, 2 Ã— 2 factorial multicenter randomized trial of 1,708 post-myocardial infarction (MI) patients â‰¥50 years of age and with creatinine â‰¤2.0 mg/dL randomized to receive 40 EDTA chelation or placebo infusions plus 6 caplets daily of a 28-component multivitamin-multimineral mixture or placebo. The primary end point was a composite of total mortality, MI, stroke, coronary revascularization, or hospitalization for angina.
RESULTS: Median age was 65 years, 18% were female, 94% were Caucasian, 37% were diabetic, 83% had prior coronary revascularization, and 73% were on statins. Five-year Kaplan-Meier estimates for the primary end point was 31.9% in the chelation + high-dose vitamin group, 33.7% in the chelation + placebo vitamin group, 36.6% in the placebo infusion + active vitamin group, and 40.2% in the placebo infusions + placebo vitamin group. The reduction in primary end point by double active treatment compared with double placebo was significant (hazard ratio 0.74, 95% CI 0.57-0.95, P = .016). In patients with diabetes, the primary end point reduction of double active compared with double placebo was more pronounced (hazard ratio 0.49, 95% CI 0.33-0.75, P < .001).
CONCLUSIONS: In stable post-MI patients on evidence-based medical therapy, the combination of oral high-dose vitamins and chelation therapy compared with double placebo reduced clinically important cardiovascular events to an extent that was both statistically significant and of potential clinical relevance.